Lymph directing prodrugs
US-2024050573-A1 · Feb 15, 2024 · US
Procaspase 3 activation by combination therapy
US9399035B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9399035-B2 |
| Application number | US-201314383441-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 6, 2013 |
| Priority date | Mar 6, 2012 |
| Publication date | Jul 26, 2016 |
| Grant date | Jul 26, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
First claim
Opening claim text (preview).
What is claimed is: 1. A composition comprising: (a) about 15 μM to about 30 μM of PAC-1: (b) about 10 μM to about 15 μM of tamoxifen; and (c) a pharmaceutically acceptable diluent, excipient, or carrier. 2. The composition of claim 1 wherein the carrier comprises water and optionally a buffer, a cyclodextrin, or a combination thereof. 3. The composition of claim 2 wherein the cyclodextrin is 2-hydroxypropyl-β-cyclodextrin. 4. The composition of claim 1 wherein the concentration of PAC-1 is to about 30 μM. 5. The composition of claim 1 , wherein the concentration of tamoxifen is about 10 μM.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
specific for leukemia · CPC title
having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title
- A61K31/138Primary
Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9399035B2 cover?
- The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combi…
- Who is the assignee on this patent?
- Hergenrother Paul J, Botham Rachel C, Fan Timothy M, and 6 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/138. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).